Momentum Biotechnologies’ Post

Are you looking for a deeper understanding of your lead candidates? 🔍 Gain specific kinetic insights into your compounds with our KinSight Time-Dependent Inhibition services. Whether your inhibition is time-dependent, reversible, or irreversible, we provide a comprehensive characterization of your compound, capturing valuable information for downstream discovery. Empower your research and accelerate your drug discovery journey with our state-of-the-art KinSight services. Learn more https://hubs.ly/Q02xtrFr0 #KinSight #TimeDependentInhibition #PhosphoSens #KinaseInhibitors #DrugDiscovery

John Baust, President and Lead Scientists at CPSI Biotech, answers questions at the last CryoChats™ entitled 'Cryopreservation Benefits and Costs of DMSO' on April 17th, 2024. Question: "For post thaw assays, it is just enough to check for flow data and compare with pre thaw numbers or is it ok to expand these cells for few days, check for viability and also carry out flow data to be sure your cryo formulation had no impact on the cells." John also provided this link as a reference: https://lnkd.in/eZN6qBUY Join us for our next CryoChats™ entitled "Cryopreservation Clinical Risks" on June 12, 2024 at 1PM CDT. Register Here: https://lnkd.in/gUXVHa83 6/12 Assessing Operational Risk and Clinical Impact 7/31 Cryopreservation Scaling

In a recent investor webinar, our Executive Director, Thomas Duthy provided an in-depth breakdown of our recent Phase I/II Clinical Trial Results for Rett Syndrome. Watch the update below as he explains the findings. You can watch the full investor webinar here:  https://lnkd.in/gWntFZps #RettSyndrome #Retts #Biotech #NTI #Neurotech

If you want to discuss about it, let’s discuss!

Come visit with myself, Dan MacDonald, and Stephen Kosteski to learn about the #BDRhapsody, talk #singlecell analysis, and discover how we can support your research needs. #NextGenOmics2024 #singlecellanalysis

📣 We are a corporate sponsor for Discovery on Target (DOT) meeting! 📆 September 30 - October 3, 2024 📍 Sheraton Boston, Boston, USA - Booth #117 The countdown to DOT is on, and we are very much looking forward to sponsoring, attending, speaking AND hosting a booth (#117). Dr. Lars Neumann, our Discovery Solutions Co-head, will be speaking on the first day at 10:30am, during Symposium 1. Title of Talk: Pocket-Specific Fragment Hits for RIPK1 and their Evolution into Long Residence Time Inhibitors Abstract: Selectivity and efficacy are typical challenges for drugs that are targeting conserved catalytic sites of protein targets. Therefore innovative drug discovery research approaches include allosteric inhibition, extended target residence time, PPI inhibitors to block protein complex formation as well as PROTAC strategies to reduce the cellular target protein concentrations. Additionally, we will also be officially launching our newest structural biology and screening capabilities! These include: ⚡️Crystallographic Fragment Screening Capability ⚡️High Throughput Screening with SPR ⚡️19-F NMR Screening If you’re attending, we look forward to seeing you there! Stop by and say hello, and if you’d like to book a meeting slot with our discovery solutions team to discuss how we can support your discovery program, please get in touch: 📩 business@proteros.com #DOT2024 #DiscoveryOnTarget #ProteinSciences #DrugDiscovery #CrystallographicFragmentScreening #HighThroughputScreening #SPR #NMRScreening #FragmentLibrary #PPIInhibitors #ProteinTargets

Fragment-based drug discovery (FBDD) has proved to be a successful paradigm in modern drug discovery. However, Ro3-compliant collections are represented mainly by flat heterocyclic structures. EDELRIS’s Fragment Collections are designed to explore 3D pockets of targets. Our talented researchers have created unique 3D pharmacophores with in-built anchoring vectors to facilitate fragment growth and linking, and their effort and engagement pay off! X-ray crystallography structures (6 depicted herein & kindly provided by our clients) have revealed the high potential of such fragments. As illustrated, Edelris 3D fragments achieve high pocket occupancy and, therefore, better selectivity towards specific pockets not occupied by conventional flat fragments. For more information: https://lnkd.in/ePkwVV4G #FBLD #drugdesign #drugdiscovery #drugdevelopment #medicinalchemistry #medchem #fragmentbasedleaddiscovery #fragmentbaseddrugdiscovery

#Singlecell Omics is a hot topic for #FOGBoston next week, and Scale Biosciences can't wait! Don't miss our talk at the Live Lounge on June 12, and be sure to join us at booth 10 to talk about #methylation, #RNAseq, #CRISPR, and more, brought to you, finally, at SCALE.

To best leverage high-resolution multi-omic technologies for drug discovery and development, the Verily Immune Profiler team conducted a systematic assessment of Xseq, our proprietary targeted mini-bulk immunophenotyping workflow, and the single cell assay. The pros and cons of each technology and recommended applications are detailed in our newest white paper: https://bit.ly/3SCirwn Single cell assay will be officially added to our Immune Profiler platform as a complementary approach to Xseq. Contact an expert to learn more: https://bit.ly/3Qqux9o #DrugDiscovery #DrugDevelopment #multiomics #SingleCell

[Join us live] 🗓️ Join Rok Sekirnik on February 21st as he talks about Why you need monoliths to purify your molecules. 💡 In this webinar, Rok explains what makes monoliths the ideal solution to the challenging requirements of purifying large biomolecules, while covering what solutions are currently available for purifying and analyzing mRNA. You will learn about: ✔️ using convective interaction chromatographic media for mRNA, pDNA, & AAV   ✔️ analytical and preparative considerations for mRNA and pDNA  ✔️ how monoliths remove critical bottlenecks for downstream purification of new modalities ✏️ Register here: https://lnkd.in/dpjwXbp8 #AAV #mRNA #biomolecules #biotech #pDNA #monoliths